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Clinically, the Fas and Fas ligand system plays a cen-
tral role in the development of hepatocyte apoptosis, a
process contributing to a broad spectrum of liver dis-
eases. Therefore, the development of therapies aimed at
the inhibition of hepatocyte apoptosis is a major issue.
Activation of the epidermal growth factor receptor has
been shown to convey survival signals to the hepatocyte.
To learn about the endogenous response of epidermal
growth factor receptor ligands during Fas-mediated
liver injury we investigated the expression of epidermal
growth factor, transforming growth factor , heparin-
binding epidermal growth factor-like growth factor, be-
tacellulin, epiregulin, and amphiregulin in the liver of
mice challenged with Fas-agonist antibody. Amphiregu-
lin expression, barely detectable in healthy liver, was
significantly up-regulated. Amphiregulin administra-
tion abrogated Fas-mediated liver injury in mice and
showed direct anti-apoptotic effects in primary hepa-
tocytes. Amphiregulin activated the Akt and signal
transducer and activator of transcription-3 survival
pathways, and up-regulated Bcl-xL expression. Amphi-
regulin knock-out mice showed signs of chronic liver
damage in the absence of any noxious treatment, and
died faster than wild type mice in response to lethal
doses of Fas-agonist antibody. In contrast, these mice
were more resistant against sublethal liver damage, sup-
porting the hypothesis that chronic liver injury can pre-
condition hepatocytes inducing resistance to subse-
quent cell death. These results show that amphiregulin
is a protective factor induced in response to liver dam-
age and that it may be therapeutic in liver diseases.
Hepatocyte apoptosis is a common mechanism to many forms
of liver disease. It has been recognized to contribute to the
pathogenesis of alcoholic liver disease, viral hepatitis, choles-
tatic liver disease, and ischemia/reperfusion injury (1–3). More
recently hepatocyte apoptosis has been reported to occur in the
liver of patients with nonalcoholic steatohepatitis, correlating
with the severity of the disease (4). The consequences of hepa-
tocellular apoptosis may extend beyond the mere loss of func-
tional liver mass, because moderate and persistent apoptosis
may contribute to the development of liver inflammation and
fibrosis (5, 6). Apoptosis can be triggered by the activation of
two molecular pathways: an intrinsic mitochondrially medi-
ated cascade and a death receptor pathway. In the liver, the
death receptor pathway appears to be predominant and in-
volves the activation of cytokine receptors such as Fas, tumor
necrosis factor receptor-1 and tumor necrosis factor-related
apoptosis-inducing ligand receptors-1 and -2 (1, 2, 6). Upon
activation by their respective ligands these receptors initiate
intracellular signaling cascades that ultimately lead to the
activation of death-inducing proteolytic enzymes (1, 2). Fas is
abundantly expressed in the liver, and Fas-mediated apoptosis
has been shown to significantly contribute to toxic or viral
damage and acute liver failure (7–9). Interestingly, hepatocyte
apoptosis observed in cholestasis is initiated by the ligand-
independent activation of Fas by hydrophobic bile salts (1, 10).
In addition, lack of Fas expression or RNA interference target-
ing of Fas results in significant protection from fulminant
hepatitis (7, 11). Altogether these observations underscore the
clinical relevance of the Fas pathway in liver disease.
The identification of agents that reduce hepatocellular apo-
ptosis is thus of special significance for the development of
hepatoprotective therapeutics (12, 13). Intensive research in
this area has shown that cytokines such as interleukin-6 (IL-
6),1 growth factors like hepatocyte growth factor, or the hepa-
tocyte-derived insulin-like growth factor binding protein-1 dis-
play potent hepatoprotective effects, including the attenuation
of apoptosis induced by Fas ligation (14–17). Activation of the
epidermal growth factor receptor (EGF-R), a transmembrane
protein endowed with tyrosine kinase activity, has been also
recognized to convey survival and proliferative signals for the
hepatocyte (18–24). Mature hepatocytes express the highest
levels of EGF-R of any normal cell type, suggesting an impor-
tant role for EGF-R signaling in liver function (25, 26). This
receptor can be bound and activated by a broad family of
ligands that, besides EGF, include transforming growth factor
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 (TGF), heparin-binding EGF-like growth factor (HB-EGF),
betacellulin (BTC), epiregulin (EPR), and amphiregulin (AR)
(27, 28). Treatment of isolated murine hepatocytes with EGF,
or transgenic overexpression of TGF in mice, have demon-
strated to induce hepatocyte resistance toward Fas-mediated
apoptosis (18, 20, 21). It is known that the expression of TGF
and HB-EGF in liver tissue is markedly increased on liver
injury induced by CCl4 (29, 30). Additionally, we have recently
reported that the expression of AR is induced in chronic liver
damage and is necessary for efficient hepatocyte DNA synthe-
sis after partial hepatectomy (31). However, to our knowledge,
the expression of these ligands in the liver during Fas-medi-
ated apoptosis has not been examined. Information on this
issue can shed light on the endogenous protective mechanisms
triggered in this clinically relevant model and help to design
therapeutic interventions. This was the original aim of this
study that led us to uncover the hepatoprotective potential
of AR.
EXPERIMENTAL PROCEDURES
Animal Experiments—Experiments were performed in conformity
with our Institution’s guidelines for the use of laboratory animals.
Acute liver damage was induced in male C57/BL6 mice (20 g) (Harlan,
Barcelona, Spain) and male AR/ and AR/ littermate mice (20 g)
(32) (n  3–5 per condition and time point), with a single intraperi-
toneal injection of the agonistic anti-Fas monoclonal antibody Jo2 (4
g/mouse in saline) (BD Pharmingen, San Diego, CA) (15). Controls
received the equivalent volume of saline. For survival experiments
male AR/ and AR/ littermate mice (20 g, n  11 mice per
genotype) received a single intraperitoneal injection of Jo2 antibody
(0.3 mg/kg of body weight). The mice were monitored for up to 24 h,
and the time of death was recorded. Where indicated mice were
injected intraperitoneally with human recombinant AR (9.5 g/
mouse, Sigma) 6 and 0.5 h prior and 3 h after anti-Fas antibody. At
the indicated time points mice were bled, and serum was analyzed for
alanine and aspartate aminotransferases (ALT and AST). Mice (C57/
BL6) were also treated with Salmonella typhimurium lipopolysaccha-
ride (15 mg/kg of body weight in saline) or CCl4 (1 l/g of body weight
in olive oil) (Sigma), intraperitoneally administered. Mice were sac-
rificed at the indicated time points by cervical dislocation, and livers
were snap frozen in liquid nitrogen or formalin-fixed and paraffin-
embedded for hematoxylin and eosin staining.
RNA Isolation and Gene Expression Analyses—Total RNA was ex-
tracted using the TRI reagent (Sigma). We treated 2 g of RNA with
DNase I (Invitrogen) prior to reverse transcription with Moloney mu-
rine leukemia virus reverse transcriptase (Invitrogen) in the presence
of RNaseOUT (Invitrogen) and used 1/10 of cDNA preparation for each
PCR. PCR products were electrophoresed in 2% agarose gels, stained
with ethidium bromide, and quantitated using the Molecular Analyst
software (Bio-Rad). Data were normalized to -actin mRNA levels. Only
samples with a comparable amplification of -actin mRNA were in-
cluded in the study. We designed all primers to distinguish between
genomic and cDNA amplification and sequenced all PCR products to
confirm the specificity.
Real-time PCR was performed using an iCycler (Bio-Rad) and the iQ
SYBR Green Supermix (Bio-Rad). To monitor the specificity final PCR
products were analyzed by melting curves and electrophoresis. The
amount of each transcript was expressed as the n-fold difference rela-
tive to the control gene -actin (2Ct, where Ct represents the differ-
ence in threshold cycle between the control and target genes), as pre-
viously described (33).
TUNEL Assay—Frozen liver tissue sections were fixed in 4% phos-
phate-buffered paraformaldehyde (pH 7.4). The TUNEL assay was
performed according to the manufacturer’s instructions (Roche Ap-
plied Science).
Isolation, Culture, and Treatment of Mouse Hepatocytes—Hepato-
cytes were isolated from male C57/BL6 mice (20 g) by collagenase
(Invitrogen) perfusion as described previously (34). Cells were plated
onto collagen-coated 6-well dishes (type I collagen, Collaborative Bio-
medical, Bedford, MA) 5  105 cells per well. Cultures were maintained
in minimal essential medium supplemented with 10% fetal calf serum,
nonessential amino acids, 2 mM glutamine, and antibiotics (all from
Invitrogen). After 2-h incubation medium was removed, and cells were
refed the same medium with 0.5% fetal calf serum.
Apoptosis was induced in cultured mouse hepatocytes by treatment
with 0.5 g/ml anti-Fas antibody and 0.05 g/ml actinomycin D as
described before (15). Where indicated hepatocytes were treated with
AR 3 h prior to addition of anti-Fas antibody and actinomycin D.
Apoptosis was estimated by the determination of soluble histone-DNA
complexes using the Cell Death Detection Assay (Roche Applied Sci-
ence). Cell death enzyme-linked immunosorbent assays were performed
according to the manufacturer’s instructions. Specific enrichment of
mono- and oligonucleosomes released into the cytoplasm (enrichment
factor) was calculated as the ratio between the absorbance values of the
samples obtained from treated and control cells. The effect of AR on
Fas-mediated apoptosis was also tested in the presence of the extracel-
lular-regulated kinase kinase-1 (MEK1) inhibitor PD98059, the phos-
phatidylinositol 3-kinase (PI3K) inhibitor LY-294002, and the EGF-R
inhibitor PD153035, all from Calbiochem. The protective effect of AR
(20 nM) on Jo2- and actinomycin D-induced apoptosis in isolated mouse
hepatocytes was also assessed by TUNEL staining. Treatments were
performed as described above; subsequently, cells were fixed in 4%
phosphate-buffered paraformaldehyde (pH 7.4) for 30 min. The TUNEL
assay was performed as recommended by the manufacturer (Roche
Applied Science).
Measurement of Caspase-3 Activity—Caspase-3 activity was meas-
ured in mouse hepatocytes and liver tissue lysates using the Caspase-
3/CPP32 Colorimetric Assay Kit (BioVision, Palo Alto, CA). Cells (5 
105) were scraped in culture medium, pelleted, and resuspended in lysis
buffer. Liver tissue was Dounce-homogenized in lysis buffer and cen-
trifuged at 15,000 rpm for 10 min. Cell lysates and supernatants from
liver homogenates (200 g in 50 l) were used to measure caspase-3
activity following the manufacturer’s instructions.
Western Blot Analysis—Homogenates from liver samples and iso-
lated hepatocytes were subjected to Western blot analysis as described
(31). Antibodies used were: affinity-purified biotinylated anti-mouse AR
polyclonal antibody (BAF989) (RD Systems), active caspase-3 p17 sub-
unit (9664S), phosphorylated Akt (Ser473) (9271S), and phosphorylated
STAT3 (Tyr705) (9131S) and phospho-JNK (9251) (Cell Signaling, Bev-
erly, MA); ERK1/2 (06–182) and STAT3 (06–596) (Upstate Biotechnol-
ogy, Charlottesville, VA). All other antibodies were from Santa Cruz
Biotechnology (Santa Cruz, CA): BclxL (sc8392), phosphorylated
ERK1/2 (Tyr204) (sc7383), Akt (sc5298), and Fas (sc1023).
Statistical Analysis—Data are the means  S.E. Statistical signifi-
cance was estimated with the Mann-Whitney test. A p value of 0.05
was considered significant.
RESULTS
Expression of EGF-R Ligands in Mouse Liver after the Ad-
ministration of the Fas-agonistic Antibody Jo2—The expres-
sion of the EGF-R ligands EGF, TGF, HB-EGF, BTC, EPR,
and AR was studied by real-time PCR in the liver of control
mice and in mice that received a dose of Jo2 antibody previ-
ously shown to cause significant liver damage and apoptosis
(15). Liver samples were taken for analysis 2, 5, and 10 h after
Jo2 administration. As depicted in Fig. 1A, serum levels of
transaminases alanine aminotransferase (ALT) and aspartate
aminotransferase (AST) were still normal 2 h after Jo2 injec-
tion, increased remarkably between 5 and 10 h of treatment,
and decreased thereafter. As shown in Fig. 1B we observed
different patterns of response to Jo2 treatment among EGF-R
ligands. HB-EGF gene expression showed a slight reduction
early after Jo2 injection, but remained close to control values
for the rest of the study. TGF gene expression showed a peak
2 h after Jo2 administration and was rapidly down-regulated,
reaching values below control levels by 10 h of treatment. EGF
gene expression did not change significantly early after Jo2
injection, but dropped below control values after 5 h of treat-
ment. Similarly, BTC gene expression was significantly down-
regulated between 2 and 5 h after Jo2 injection and remained
so at the last time point tested. The two other EGF-R ligands
examined, namely AR and EPR, showed a clear up-regulation
in Jo2-treated mice. EPR gene expression was progressively
induced, being maximal 10 h post-Jo2 administration, the lat-
est time point tested. Interestingly, in agreement with other
reports and our previous observations we noticed that AR gene
expression was barely detectable in normal liver (35, 36); how-
ever, it was potently induced between 2 and 5 h after Jo2
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injection, preceding that of EPR. In concordance with the up-
regulation of AR mRNA levels, Western blot analyses per-
formed with a biotinylated affinity-purified anti-mouse AR an-
tibody on liver samples obtained 10 after Jo2 antibody
administration allowed us to detect a set of proteins that were
present in the liver of treated mice (Fig. 2). Four bands of 50,
43, 28, and 19 kDa are consistent with the different forms of AR
described in epithelial cells (36). The 50- and 28-kDa bands
likely represent membrane-anchored forms of AR, whereas the
43- and 19-kDa bands may be proteolytically processed soluble
forms of AR (36). The fact that AR gene expression becomes
induced during the early time period following Jo2 treatment
suggested that AR may be protective against Fas-mediated
apoptosis. This observation led us to evaluate the in vivo hepa-
toprotective effects of this EGF-R ligand.
AR Administration Attenuates Fas-mediated Acute Liver In-
jury in Mice—To test if AR can limit the extent of liver injury
we examined the effect of AR administration in mice chal-
lenged with Jo2 antibody. Serum levels of ALT and AST were
greatly elevated 10 h after Jo2 injection (Fig. 3A). AR treat-
ment potently suppressed liver damage, as indicated by the
reduced levels of serum transaminases and histopathological
analysis of liver tissue sections from AR-treated mice, showing
how this growth factor prevented the destruction of the paren-
chymal architecture induced by Fas ligation (Fig. 3A). As men-
tioned above, apoptotic cell death is a major determinant in
Fas-mediated liver damage. To confirm that the hepatoprotec-
tive effects of AR against Fas-mediated liver injury derived
from an anti-apoptotic action, we performed TUNEL staining
and measured caspase-3 cleavage and activity in mouse liver
extracts. TUNEL staining showed profuse apoptotic injury in
Jo2-treated mice (Fig. 3B), which was confirmed by cleavage
and activation of caspase-3 (Fig. 3, C and D). All these apo-
ptosis-related events were significantly prevented by AR treat-
ment (Fig. 3, B–D). Prevention of caspase-3 cleavage by AR
suggests the specific blockade of Fas-induced apoptotic path-
way by this growth factor (Fig. 3D). Bcl-2 family proteins in-
hibit apoptosis induced by variety of stimuli, including Fas-
mediated apoptosis (37–39). We assessed the expression of the
antiapoptotic protein Bcl-xL by Western blotting 10 h after the
injection of anti-Fas antibody. Bcl-xL proteins levels were de-
creased in the liver of mice treated with Jo2; however, AR
administration helped to maintain the Bcl-xL protein levels
found in control mouse liver (Fig. 3D).
Interestingly, AR mRNA levels are also rapidly induced
(between 2 and 3 h) in other models of hepatic injury such as
acute CCl4 or bacterial lipopolysaccharide administration
(data not shown). CCl4 causes necrosis and apoptosis in liver
cells through the promotion of membrane lipid peroxidation
and the production of high levels of tumor necrosis factor 
(40, 41). The administration of AR 0.5 h prior and 12 h after
CCl4, significantly prevented the development of tissue in-
jury and the rise in serum transaminases: from 9193  908
IU/ml ALT in CCl4-treated mice to 4688  735 IU/ml ALT in
CCl4 plus AR-treated mice, p  0.05. In the same animals AST
levels were reduced from 8579  684 to 4475  773 IU/ml in
AR-treated mice, p  0.05.
Direct Antiapoptotic Effect of AR on Primary Cultured Hepa-
tocytes—To determine whether the in vivo antiapoptotic effects
of AR could be mediated by a direct action of AR on the liver
FIG. 1. A, serum levels of ALT and AST (102 IU/liter) at different
time points after Jo2 antibody injection in mice. B, gene expression
profiles of different EGF-R ligands in the liver of control mice (C), and
at various times after Jo2 antibody injection as determined by real-time
PCR (n  4 animals per point). BTC, betacellulin; EPR, epiregulin;
TGF, transforming growth factor ; EGF, epidermal growth factor;
HB-EGF, heparin-binding EGF; AR, amphiregulin. Asterisks indicate
p  0.05 versus control mice.
FIG. 2. A, AR gene expression was assessed by RT-PCR in the liver of
control mice and in the liver of mice treated with Jo2 antibody for 5 h.
B, Western blot analysis of liver extracts from control and Jo2-treated
mice performed with a biotinylated affinity purified anti-AR antibody.
Samples were obtained after 10 h of treatment with Jo2 antibody.
Arrowheads indicate the different AR forms. Three representative sam-
ples are shown per group.
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parenchymal cells, we used mouse hepatocytes in primary cul-
ture. It has been described that hepatocytes exposed to anti-
Fas antibodies (Jo2) efficiently undergo apoptosis in the pres-
ence of actinomycin D (15, 18, 42). Hepatocytes were pretreated
with different concentrations of AR for 3 h prior to actinomycin
D and Jo2 antibody addition. Apoptosis, and apoptosis-related
molecular events, were measured 18 h later. As shown in Fig.
4A, AR dose-dependently protected hepatocytes from apoptosis
indicating a direct cytoprotective effect of AR in the prevention
of Fas-mediated liver apoptosis. The antiapoptotic effect of AR
was further demonstrated by TUNEL staining of isolated hepa-
tocytes treated with Jo2 plus actinomycin D. As shown in Fig.
4B the number of TUNEL-positive cells was significantly re-
duced in AR-treated cultures. Interestingly, the cytoprotective
activity of AR was also observed in apoptosis induced by other
agents such as okadaic acid, TGF, and tumor necrosis factor 
plus galactosamine (data not shown). In concordance with the
antiapoptotic effect of AR, we observed that caspase-3 cleavage
and activation induced by anti-Fas antibody were significantly
inhibited by AR (Fig. 4C). In agreement with our previous
observations performed in vivo, we found that, although the
levels of the antiapoptotic protein Bcl-xL were reduced in hepa-
tocytes undergoing apoptosis they were maintained in the pres-
ence of AR (Fig. 4C). On the other hand, Bcl-2 protein was not
detected in any sample (data not shown).
To learn about the antiapoptotic signaling of AR, we exam-
ined the PI3K/Akt and ERK1/2 (extracellular-regulated kinase
1/2) pathways, general mediators of cell survival (24, 43–46).
Mouse hepatocytes in culture treated with AR showed in-
creased phosphorylation of Akt and ERK1/2 (Fig. 5A). Another
key signaling molecule involved in the protection from apo-
ptosis, including Fas-mediated apoptosis of murine hepato-
cytes, is signal transducer and activator of transcription 3
(STAT3) (24, 47). We observed that AR stimulated STAT3
phosphorylation (Tyr705), an indicator of STAT3 activation
(Fig. 5A).
The activation of the EGF-R by AR seems to be essential in
the mediation of the antiapoptotic effect of this growth factor on
Fas-induced cell death. This became evident when mouse hepa-
tocytes were pretreated for 1 h with the EGF-R inhibitor
PD153035 before addition of AR, and the protection afforded by
AR was lost (Fig. 5B). Downstream of EGF-R, the activation of
the PI3K/Akt pathway by AR was also necessary to prevent
apoptosis, as demonstrated by the marked inhibitory effect of
the PI3K inhibitor LY294002 (Fig. 5B). However, the MEK1
inhibitor PD98059 did not interfere with the antiapoptotic ef-
fect of AR (Fig. 5B).
Response of AR/ Mice to Anti-Fas Antibody Administra-
tion—Once established the antiapoptotic effects of AR on liver
parenchymal cells and to further define the role of AR expres-
sion in liver damage, we examined the response of AR/mice
to Fas ligation. Unexpectedly, serum transaminases measured
at different time points after Jo2 antibody administration were
significantly higher in wild type (AR/) mice when compared
with the knock-out littermates (AR/) (Fig. 6A). In agree-
ment with the higher degree of liver injury found in AR/
FIG. 3. AR administration prevents Fas-induced acute liver damage. A, effect of AR pretreatment on serum transaminases and liver
histology in mice treated with Jo2 antibody (hematoxylin and eosin staining, original magnification, 200). Sera and tissue samples were taken
10 h after Jo2 administration. Values are means  S.E. of three experiments performed in triplicate. *, p  0.01 versus Jo2 alone. B, TUNEL
staining (arrows) of liver sections from mice treated with Jo2 or Jo2 plus AR as described in panel A. Representative samples are shown; original
magnification, 200. C, caspase-3 activity in mouse liver. Liver extracts were prepared 12 h after Jo2 injection. Where indicated mice were
pretreated with AR. Values are means  S.E. of three experiments performed in triplicate. *, p  0.01 versus Jo2 alone. D, Western blot analysis
of active caspase-3 p17 subunit and Bcl-xL proteins in control mouse liver (“C ”) and in liver extracts obtained 10 h after Jo2 injection. Where
indicated mice were pretreated with AR. Membranes were probed for actin as loading control. Representative blots are shown.
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mice, we also observed that the extent of caspase-3 activation
6 h after Jo2 administration, as determined by the appearance
of its p17 cleavage product, was more pronounced in AR/
mice than in the AR/ counterparts (Fig. 6B). In addition, the
induction of stress-activated pathways, such as that triggered
by Jun N-terminal kinase (JNK) in response to Fas ligation
(48), was markedly blunted in AR/ mice (Fig. 6C). The
increased resistance to Jo2 cell death in these knock-out mice
was not due to a decreased expression of Fas receptor in liver
tissue (Fig. 6D). Interestingly, the reduced vulnerability to
liver injury of AR/ mice was not restricted to Fas-mediated
liver damage, because it was also observed for other hepatotox-
ins such as CCl4 (data not shown).
Although to a lesser extent than wild type mice, AR/mice
are also vulnerable to liver damage-inducing agents. To further
demonstrate the protective effects of AR in Fas-mediated liver
injury, AR/ mice were treated with AR and challenged with
Jo2 antibody. As shown in Fig. 6E, AR treatment attenuated
liver injury as judged by serum AST levels measured at 12 h
after Jo2 administration. In concordance with the reduced AST
levels, prevention of caspase-3 cleavage by AR was also ob-
served (Fig. 6F). These observations suggest that exogenous
AR can enhance the protective mechanisms that apparently
operate in AR/ mice.
Finally, we tested the response of AR/ and AR/mice to
a lethal dose of Jo2 antibody (0.3 mg/kg, intraperitoneal) (n 
11 mice per genotype). Although we observed similar lethality
for both strains as assessed 24 h after antibody injection (8/11
for AR/ and 9/11 for AR/), AR/ mice showed a sur-
vival advantage over AR/ animals. Most (8/11) of the
AR/mice that died in response to Jo2 challenge did so in the
first 6 h post antibody injection, whereas by that time only one
wild type mouse had died. These data suggest that the persis-
tent liver injury observed in AR/ mice, which can confer a
certain degree of resistance to sublethal liver damage, does not
afford enhanced survival in life-threatening liver injury.
Lack of AR Results in Chronic Liver Damage: Potential
Mechanisms for Cell Death Resistance—Our primary observa-
tions showing the hepatoprotective potential of AR on Fas-
mediated liver damage seemed to be at odds with the resistance
FIG. 4. Antiapoptotic effect of AR on primary mouse hepatocytes. A, apoptosis was induced in primary cultured mouse hepatocytes by
actinomycin D and Jo2 treatment in the presence of increasing concentrations of AR. Apoptosis was assessed by measuring specific enrichment of
mono- and oligonucleosomes released into the cytoplasm (enrichment factor (EF)), and was calculated as the ratio between the absorbance values
obtained in treated samples and controls (“C”). Values are means  S.E. of three experiments performed in triplicate. *, p  0.05 versus Jo2. B,
TUNEL staining (arrows) of isolated and cultured mouse hepatocytes in which apoptosis was induced by actinomycin D and Jo2 treatment in the
presence or absence of AR (20 nM). Representative fields are shown; original magnification, 200. C, effect of AR (20 nM) on caspase-3 activity in
cultured mouse hepatocytes treated with actinomycin D and Jo2. Values are means S.E. of three experiments performed in triplicate. *, p 0.05
versus cells treated with actinomycin D and Jo2. Representative Western blot analyses of active caspase-3 p17 subunit and Bcl-xL proteins are
shown.
FIG. 5. A, activation of antiapoptotic signaling pathways by AR in cultured mouse hepatocytes. The phosphorylation state of Akt, ERK1/2, and
STAT3 was assessed by Western blotting in extracts of mouse hepatocytes at different times after AR (10 nM) addition. Representative blots of three
experiments performed in duplicate are shown. B, effect of AR (20 nM) on actinomycin D and Jo2-induced apoptosis in cultured mouse hepatocytes
in the presence of the EGF-R inhibitor PD153035 (1 M), the MEK1 inhibitor PD98059 (10 M), or the PI3K inhibitor LY294002 (30 M). Values
are means  S.E. of three experiments performed in triplicate. *, p  0.05 versus Jo2.
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to apoptosis and necrosis-like cell death observed in AR/
mice challenged with anti-Fas antibody or CCl4. However,
there is accumulating evidence showing that a pre-existing
liver damage can precondition hepatocytes and result in a
certain degree of cell death resistance. This phenomenon is
widely recognized in the field of liver surgery and transplanta-
tion, where acute cell stress or injury induced by ischemic
preconditioning can protect against subsequent reperfusion in-
jury (49, 50). More recently, the protective effects of a pre-
existing chronic liver disease have also been identified in a
murine model of hereditary tyrosinemia (48). Considering this
hypothesis, we went on to examine whether AR/ mice dis-
played signs of chronic liver damage that might precondition
hepatocytes against cell death. As shown in Fig. 7A, the basal
levels of serum transaminases were significantly higher in
AR/ mice as compared with wild type animals. We also
observed that the hepatic mRNA levels of cistathionine -syn-
thase and the modifier subunit of -glutamylcysteine synthe-
tase, two enzymes that are induced under oxidative stress (34,
51), were up-regulated in AR null mice (Fig. 7B). Furthermore,
analysis of caspase-3 activation, by detection of its p17 cleavage
product, showed that mice lacking AR, but not wild type mice,
displayed a basal activation of this apoptosis-related event
(Fig. 7C). As previously mentioned, the STAT3 pathway is a
major hepatoprotective effector activated in the liver as defense
mechanism against apoptotic cell death (24, 47, 52). We ob-
served that AR/ mice showed enhanced levels of STAT3
phosphorylation (Tyr705) in the liver (Fig. 7D), suggesting the
existence of an endogenous protective response against the
ongoing liver damage. Cytokines and growth factors with hepa-
toprotective activity such as IL-6, cardiotrophin-1, and EGF,
are known to activate and likely mediate their survival effects
through the STAT3 pathway (52–55). Because AR is a member
of the EGF-R family of ligands, we first tested the expression of
other EGF-R ligands in the liver of AR/ mice that could
compensate for the lack of AR and play a role in the resistance
to cell death. We did not observe any significant differences in
the basal expression levels of EGF, TGF, EPR, HB-EGF, or
BTC mRNAs between the two strains of mice (data not shown).
Similarly the expression of the IL-6 family member cardiotro-
phin-1 was not different between AR wild type and knock-out
mice (data not shown). However, the basal mRNA levels of IL-6
in the liver of AR/ mice were significantly higher (2.5-fold)
than in wild type mice (Fig. 8). IL-6 is a critical proregenerative
factor and a major regulator of the acute phase response (52),
its up-regulation in AR/ mice may be indicative of an ongo-
ing stress condition and may play an important role in the
enhanced resistance of these mice to acute liver damage. In line
with the essential functions of IL-6 we observed that its expres-
sion was rapidly and markedly induced in the liver of wild type
mice shortly after the injection of Jo2 antibodies (Fig. 8). In-
terestingly, the up-regulation of IL-6 gene expression in the
FIG. 6. Response of AR/ mice to acute liver damage induced by Fas ligation. A, serum levels of ALT in wild type and AR knock-out
mice at 5 and 10 h after Jo2 injection. *, p  0.05 versus wild type mice. B, representative Western blot analysis of active caspase-3 p17 subunit
in wild type and AR knock-out mice 5 h after Jo2 injection. C, phosphorylation of JNK in the liver of wild type and AR knock-out mice 5 h after
Jo2 injection. D, expression levels of Fas receptor in wild type and AR knock-out mice. Representative blots are shown. E, effect of AR pretreatment
on serum transaminases in AR/mice 12 h after Jo2 injection. Values are means  S.E. of three experiments performed in triplicate. *, p  0.05
versus Jo2 alone. F, Western blot detection of caspase-3 p17 cleavage product in the liver of AR knock-out mice 12 h after Jo2 injection and the effect
of AR pretreatment. Representative blots are shown.
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liver of AR/ mice after Jo2 administration was markedly
blunted (Fig. 8). The attenuation of this protective response
may be a consequence of the pre-existing hepatoprotective
mechanisms triggered in AR knock-out mice.
DISCUSSION
The identification of endogenous protective mechanisms trig-
gered upon liver injury is important not only for the study of
the pathophysiology of this organ, but also for the design of
more effective therapies that potentiate the natural defensive
responses (13, 24, 56). The EGF-R is highly expressed in the
hepatocyte and seems to be a relevant mediator of survival and
proliferative responses (18–20, 25–27). Activation of the
EGF-R by EGF administration or the overexpression of TGF
in transgenic mice has been shown to efficiently protect hepa-
tocytes from apoptotic cell death (19, 21). However, the expres-
sion profiles of these and other EGF-R ligands during acute
liver damage induced by Fas ligation have not been defined. In
the present work we observed that the mRNA levels of TGF
and AR were up-regulated early after Fas-agonist antibody
administration, suggesting that these factors may be protective
against Fas-mediated apoptosis. Particularly noteworthy was
the marked up-regulation of mRNA and protein levels of AR, a
growth factor that in contrast to the other EGF-R ligands is
barely detectable in the healthy normal human and rodent
liver (35). Recently we have shown that the expression of AR is
induced in chronic experimental liver damage and in human
liver cirrhosis and is readily detected in rodent liver after
partial hepatectomy (31). Moreover, AR seems necessary for
adequate DNA synthesis during mouse liver regeneration (31).
Now we observe that AR is rapidly induced in the mouse liver
upon Fas-mediated acute liver damage.
The biological significance of AR up-regulation under these
circumstances can be inferred from our experiments in which
treatment with recombinant AR significantly prevented Fas-
mediated hepatocellular death in vivo. Furthermore, the hepa-
toprotective effect of AR could be extended to acute liver dam-
age mediated by CCl4. We observed that AR administration
blocked the Fas-mediated signal transduction pathway up-
stream of caspase-3 activation. This effect could be mediated in
part by its ability to preserve the expression of the antiapo-
ptotic protein Bcl-xL, which has been involved in the suppres-
sion of liver apoptosis driven by Fas antibody injection (14).
Experiments conducted in isolated mouse hepatocytes evi-
denced that AR can directly interact with the parenchymal
liver cells and trigger survival signals. We have recently shown
that AR can induce the synthesis of DNA in isolated hepato-
cytes through the activation of the EGF-R (31), and our current
in vitro experiments show that the activation of the EGF-R by
AR is also necessary to convey its antiapoptotic effect. The
ability to induce cellular proliferation is often correlated with
the promotion of survival (24), and the downstream PI3K,
ERK1/2, and STAT3 pathways have been shown to be major
regulators of cell proliferation and survival in response to
growth factors (24, 43–47, 57). Our data indicate that the
antiapoptotic activity of AR on Fas-mediated cell death is in-
dependent of the ERK1/2 pathway but dependent of PI3K.
Additionally, we also demonstrate that AR activates STAT3, a
factor that might also be involved in the hepatoprotective ef-
fects of AR.
To gain further insight into the role of AR production during
liver damage we made use of AR null mice (32). Unexpectedly,
we found that AR/ mice were clearly more resistant to liver
damage induced by Fas ligation, and CCl4 administration, than
their wild type counterparts. These observations seemed to be
at variance with our previous evidences showing that AR ad-
ministration abrogated Fas-mediated cell death both in vivo
and in vitro and prevented CCl4-mediated liver damage. En-
hanced resistance to liver injury has been described in animals
FIG. 7. AR/ mice show signs of
chronic liver injury. A, basal levels of
ALT were elevated in AR null mice. *, p 
0.05. B, expression of cystathionine -syn-
thase and -glutamylcysteine synthetase
genes in the liver of wild type and AR
knock-out mice determined by quantitative
real-time PCR. *, p  0.05 with respect to
AR/ mice. C, Western blot detection of
caspase-3 p17 cleavage product in the liver
of AR knock-out mice. D, basal levels of
STAT3 Tyr705 phosphorylation in the livers
of wild type and AR knock-out mice. Rep-
resentative blots are shown.
FIG. 8. Expression of IL-6 mRNA in the liver of AR/ and
AR/ mice before and after the intraperitoneal injection of
Jo2 antibody. Expression levels were determined by quantitative real-
time PCR. *, indicates p  0.05 with respect to untreated AR/ mice.
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that undergo different forms of acute or chronic liver damage.
Probably the best-characterized example of this response is the
ischemic preconditioning in the prevention of ischemia-reper-
fusion liver injury (49, 50). The protective effect of sublethal
doses of anti-Fas antibodies toward the lethal effects of higher
doses of such antibodies has also been recognized (58). More
recently the enhanced resistance of the chronically injured
liver to subsequent damage has been substantiated in an ex-
perimental model of hereditary tyrosinemia (fumarylacetoac-
etate hydrolase-deficient, FAH/, mice) (48). Pre-existing
chronic liver damage in these mice resulted in protection from
ethanol, acetaminophen, and Fas-mediated liver injury and
apoptosis (48). Interestingly, similar to what has been observed
in the apoptosis-resistant FAH/ mice (48), AR null mice
displayed blunted activation of the apoptosis-associated kinase
JNK upon Fas ligation. In light of these observations, we were
prompted to consider the possibility that lack of AR could
contribute to the generation of chronic liver damage that would
precondition AR/ mice against subsequent liver injury. The
examination of different parameters indicative of liver damage
such as serum transaminases and the expression of genes
involved in adaptation to oxidative stress and caspase-3 acti-
vation suggested indeed that lack of AR may result in the
development of mild chronic liver injury. This situation entails
the triggering of a protective response in the liver of AR/
mice, phenotypically manifested as the enhanced resistance to
Fas- and CCl4-mediated hepatotoxicity. Interestingly, this
compensatory response seemed not to be mediated by other
members of the EGF-R family of ligands, because their expres-
sion was not induced in the liver of AR/ mice. Instead we
found that the basal levels of IL-6 were significantly up-regu-
lated in the liver of these animals and were not further induced
upon Fas challenge as happened in wild type mice. The blunted
induction of IL-6 expression in AR/ mice after anti-Fas
antibody administration may be explained by the pre-existing
cell death resistance state. This condition would limit the ex-
tent of tissue damage and the concomitant endogenous protec-
tive response mediated in part by IL-6. Consistent with this we
observed that the levels of STAT3 (Tyr705) phosphorylation,
implicated in the signaling of the hepatoprotective effects of
IL-6 (52, 53), were enhanced in AR/ mice. The activation of
these protective mechanisms may also explain the blunted
response of stress-activated pathways such as JNK upon Fas
challenge in AR null mice (59, 60). Although at the present time
we cannot exclude other mechanisms implicated in the en-
hanced resistance of AR/ mice to hepatocellular damage
besides IL-6 up-regulation, our current observations support
the hypothesis formulated by Vogel et al. (48) that persistent
liver injury may induce resistance to subsequent cell death.
Altogether our findings show that AR gene expression is
rapidly and consistently induced in different models of liver
injury, including the administration of bacterial lipopolysac-
charide, suggesting that AR may be part of the primary defen-
sive response of this organ. The response of AR to lipopolysac-
charide is of particular relevance, because the liver is
continuously exposed to endogenous endotoxins from the co-
lonic Gram-negative flora that reach the portal circulation (61).
It is thus possible that, among the potent defensive mecha-
nisms that the liver has developed to resist intestine-derived
noxious stimuli, AR might be one of them. In this context, an
impaired induction of AR, as occurs in AR knock-out mice, may
contribute to the development of the chronic liver damage
observed in these animals. Interestingly, although the mild
chronic liver injury that spontaneously develops in AR-defi-
cient mice affords protection toward sublethal liver damage,
these animals seem to be at a disadvantage when facing life-
threatening Fas stimulation. These observations, together with
the hepatoprotective effect of exogenous AR in AR/ mice,
further underscore the essential role of AR in the protection
from liver injury. In summary, our present observations reveal
a novel hepatoprotective role of AR and suggest that this factor
may be of therapeutic value for patients with liver disease.
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